Organon & Co. (OGN) — closed signal from December 11, 2025
Target reached Published before the outcome was known, scored automatically when the window closed on March 11, 2026 — -11% at the close.
Predicted vs. what happened
What happened
Reached its target in 40 days.
The thesis — published December 11, 2025
Organon looks cheap and has good public interest, but its business results are weak, so it's a risky turnaround play rather than a reliable holding. Recent FDA approval for an oncology biosimilar is a real win, yet a major bank started a negative rating and sales are shrinking, so any recovery could be uneven and needs careful watching.
Primary drivers
- Low forward price relative to earnings makes it look like a bargain.
- Price action suggests early signs of stabilizing after declines.
- FDA approval for POHERDY boosts the oncology biosimilars lineup.
- Negative analyst rating and falling sales warn of continued risk.
How it played out
OGN: target reached in 40 days
Lyra published OGN at $7.28 on 2025-12-11 with expected growth of 22%. The thesis was a risky turnaround setup, not a reliable holding. It pointed to a low forward price relative to earnings, early price stabilization, FDA approval for POHERDY, and risks from a negative analyst rating and falling sales.
Inside the window, the stock reached the $8.88 target in 40 days. It peaked at $9.94 on 2026-01-23, with a 36.5% gain. By 2026-03-11, it had fallen to $6.48. The thesis played out on the target, but the move did not hold through the window.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.